436 articles with Evotec AG
Evotec SE announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2019 with very strong supporting majorities.
“We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.
Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.
Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.
Eur 140 m bridge loan was drawn to secure evotec's value chain expansion by successful acquisition of aptuit in august 2017
Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer
The collaboration leverages indivumed's true multi-omics cancer database "Indivutype" and evotec's drug discovery platforms to identify new therapeutics for colorectal cancer
Evotec SE announced that it has completed its conversion into a company under European law with its registration in the commercial register of the District Court of Hamburg.
Evotec And The Mark Foundation For Cancer Research Announce Strategic Collaboration In Immuno-oncology
Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec's new allosteric inhibitor platform "Targetallomod"
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets
Evotec AG announced that its management will be presenting at and attending the following upcoming conferences:
Evotec Receives Milestone Payment For Start Of Second Phase Ii Trial In Its Multi-target Alliance With Bayer
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.
Evotec and helmholtz aim to jointly develop cystobactamid derivatives into a new class of broad spectrum antiobiotics targeting high-priority pathogens
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.
Evotec's partner, second genome, begins a phase ii clinical trial for nash with licensed molecule, sgm-1019